The Aroon Indicator for APYX entered a downward trend on October 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 248 similar instances where the Aroon Indicator formed such a pattern. In 239 of the 248 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APYX's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on APYX as a result. In 83 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for APYX just turned positive on October 12, 2026. Looking at past instances where APYX's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where APYX advanced for three days, in 198 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
APYX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.521) is normal, around the industry mean (2.874). P/E Ratio (-12.050) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.196) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. APYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NVNO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 22, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 41 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for NVNO entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVNO's RSI Indicator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVNO advanced for three days, in 191 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
NVNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.232) is normal, around the industry mean (2.874). P/E Ratio (-0.277) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. NVNO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVNO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
APYX | NVNO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 86 | |
P/E GROWTH RATING 1..100 | 13 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APYX's Valuation (23) in the Medical Specialties industry is in the same range as NVNO (40) in the null industry. This means that APYX’s stock grew similarly to NVNO’s over the last 12 months.
APYX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVNO (100) in the null industry. This means that APYX’s stock grew similarly to NVNO’s over the last 12 months.
NVNO's SMR Rating (98) in the null industry is in the same range as APYX (99) in the Medical Specialties industry. This means that NVNO’s stock grew similarly to APYX’s over the last 12 months.
APYX's Price Growth Rating (80) in the Medical Specialties industry is in the same range as NVNO (86) in the null industry. This means that APYX’s stock grew similarly to NVNO’s over the last 12 months.
APYX's P/E Growth Rating (13) in the Medical Specialties industry is in the same range as NVNO (15) in the null industry. This means that APYX’s stock grew similarly to NVNO’s over the last 12 months.
| APYX | NVNO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 79% | N/A |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Advances ODDS (%) | 2 days ago 85% | 16 days ago 76% |
| Declines ODDS (%) | 4 days ago 89% | 1 day ago 85% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APYX’s FA Score shows that 2 FA rating(s) are green while NVNO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APYX’s TA Score shows that 5 TA indicator(s) are bullish while NVNO’s TA Score has 5 bullish TA indicator(s).
APYX (@Medical/Nursing Services) experienced а -2.33% price change this week, while NVNO (@Medical/Nursing Services) price change was -0.95% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
APYX is expected to report earnings on Nov 05, 2026.
NVNO is expected to report earnings on Oct 30, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor tells us that APYX and ITOC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APYX and ITOC's prices will move in lockstep.
| Ticker / NAME | Correlation To APYX | 1D Price Change % | ||
|---|---|---|---|---|
| APYX | 100% | -3.98% | ||
| ITOC - APYX | 26% Poorly correlated | -8.24% | ||
| CLPT - APYX | 25% Poorly correlated | N/A | ||
| EMBC - APYX | 25% Poorly correlated | +2.69% | ||
| A - APYX | 25% Poorly correlated | -2.17% | ||
| NVNO - APYX | 25% Poorly correlated | -5.73% | ||
More | ||||
A.I.dvisor tells us that NVNO and HBIO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVNO and HBIO's prices will move in lockstep.
| Ticker / NAME | Correlation To NVNO | 1D Price Change % | ||
|---|---|---|---|---|
| NVNO | 100% | -5.73% | ||
| HBIO - NVNO | 31% Poorly correlated | -1.77% | ||
| DHR - NVNO | 31% Poorly correlated | -1.76% | ||
| RGEN - NVNO | 30% Poorly correlated | -0.72% | ||
| TWST - NVNO | 30% Poorly correlated | -9.16% | ||
| RDNT - NVNO | 28% Poorly correlated | +2.70% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FEMD | 34.97 | N/A | N/A |
| First Eagle Mid Cap Equity ETF (FEMD) | |||
| GLU | 17.56 | -0.14 | -0.79% |
| Gabelli Utility & Income Trust (The) | |||
| DWMF | 32.56 | -0.52 | -1.58% |
| WisdomTree International Multifactor Fund (DWMF) | |||
| OAIM | 45.56 | -0.91 | -1.96% |
| OneAscent International Equity ETF (OAIM) | |||
| XSOE | 43.36 | -1.30 | -2.91% |
| WisdomTree Emerging Markets ex-State-Owned Enterprises Fund (XSOE) | |||